keyword
MENU ▼
Read by QxMD icon Read
search

golimumab

keyword
https://www.readbyqxmd.com/read/29773268/recent-therapeutic-advances-in-juvenile-idiopathic-arthritis
#1
REVIEW
Gabriella Giancane, Alessandra Alongi, Silvia Rosina, Jessica Tibaldi, Alessandro Consolaro, Angelo Ravelli
Over the past two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by the increased tendency toward early aggressive interventions and the availability of the novel biologic medications. In 2017, three novel randomized controlled trials have evaluated the effectiveness and tolerability of golimumab and tocilizumab in polyarticular JIA, and shown that methotrexate may increase and prolong the effect of intra-articular corticosteroid injection in children with oligoarthritis...
August 2017: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/29752584/correction-to-regional-differences-in-baseline-disease-activity-and-remission-rates-following-golimumab-treatment-for-ra-results-from-the-go-more-trial
#2
Patrick Durez, Karel Pavelka, Maria Alicia Lazaro, Abraham Garcia-Kutzbach, Robert J Moots, Howard Amital, Marinella Govoni, Nathan Vastesaeger
The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.
May 12, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29751529/the-use-and-safety-of-tnf-inhibitors-during-pregnancy-in-women-with-psoriasis-a-review
#3
REVIEW
Cæcilie Bachdal Johansen, Espen Jimenez-Solem, Ann Haerskjold, Freja Lærke Sand, Simon Francis Thomsen
Psoriasis is a chronic immune-mediated inflammatory disease affecting women of childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are the only current non-contraindicated systemic treatment option during pregnancy. TNFi comprised of complete immunoglobulin G (IgG) antibodies antibodies (adalimumab, golimumab, and infliximab) actively cross the placenta from the second trimester and are detectable in the child up to one year postpartum. Data on safety of TNFi are conflicting; however a trend towards drug-specific harm has been reported, with increased risk of congenital malformations and preterm birth...
May 3, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29731461/-diagnosis-and-treatment-of-rheumatoid-arthritis-toward-the-best-practice-the-best-practice-for-tnf-inhibitors
#4
Hideto Kameda
As of February 2018, 5 originator TNF inhibitors(infliximab, etanercept, adalimumab, golimumab and certolizumab pegol)and biosimilar agents of infliximab and etanercept are available for rheumatoid arthritis(RA)in Japan. The effectiveness of TNF inhibitors considerably improves with concomitant methotrexate regardless of their immunogenicity. The Japan College of Rheumatology guideline for TNF inhibitor use in RA has been updated in March 2017 according to recent evidences. During the remission induction phase, maintenance of drug trough level above effective blood concentration is paramount, while the tapering and withdrawal of TNF inhibitors may be considered after achieving sustained remission...
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29718743/a-real-world-multi-site-observational-study-of-infusion-time-and-treatment-satisfaction-with-rheumatoid-arthritis-patients-treated-with-intravenous-golimumab-or-infliximab
#5
Shoshana R Daniel, John D McDermott, Cathy Le, Christine A Pierce, Michael A Ziskind, Lorie A Ellis
OBJECTIVES: To assess real-world infusion times for golimumab (GLM-IV) and infliximab (IFX) for rheumatoid arthritis (RA) patients and factors associated with treatment satisfaction. METHODS: An observational study assessed infusion time including: clinic visit duration, RA medication preparation and infusion time, and infusion process time. Satisfaction was assessed by a modified Treatment Satisfaction Questionnaire for Medication (patient) and study-specific questionnaires (patient and clinic personnel)...
May 2, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29718241/cost-effectiveness-of-different-strategies-for-the-treatment-of-moderate-to-severe-ulcerative-colitis
#6
Bin Wu, Zhenhua Wang, Qiang Zhang
Background: Knowledge regarding the economic outcomes of anti-tumour necrosis factor-α (anti-TNFα) and oral Janus kinase inhibitor (JAKi) therapies for the treatment of ulcerative colitis (UC) is limited. We conducted this analysis to assess the economic outcomes of anti-TNFα, antiadhesion molecule inhibitors (anti-AMi), and oral JAKi therapies for the treatment of UC from the perspectives of the United Kingdom (UK) and China, which are the representatives of high-income and middle-income regions, respectively...
April 27, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29717037/the-effect-of-biologic-and-targeted-synthetic-drugs-on-work-and-productivity-related-outcomes-for-patients-with-psoriatic-arthritis-a-systematic-review
#7
Nicolas Iragorri, Mark Hofmeister, Eldon Spackman, Glen S Hazlewood
OBJECTIVE: To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity. METHODS: A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period...
May 1, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29705819/paradoxical-pustular-psoriasis-induced-by-ustekinumab-in-a-patient-with-crohn-s-disease-associated-spondyloarthropathy
#8
REVIEW
Michael Benzaquen, Benoit Flachaire, Frank Rouby, Philippe Berbis, Sandrine Guis
Palmoplantar pustular psoriasis (PPP) is a clinical form of psoriasis, for which tumor necrosis factor alpha inhibitors (TNFi) or interleukins 12/23 inhibitor (ustekinumab) can be a therapeutic option. Paradoxical psoriatic reactions induced by TNFi are now well known. We present the exceptional case of a paradoxical PPP appeared under ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. A 58-year-old woman presented with recent peripheral inflammatory arthralgias appeared in the context of a Crohn's disease diagnosed in 2008...
April 28, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29667098/treatment-patterns-among-patients-with-rheumatic-disease-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-psoriatic-arthritis-psa-and-undifferentiated-arthritis-una-treated-with-subcutaneous-tnf-inhibitors
#9
Kathleen Tymms, Geoff Littlejohn, Hedley Griffiths, Julien de Jager, Paul Bird, Fred Joshua, Peter Nash, Malcolm Handel, Hamish McManus, Belinda E Butcher, Peter Youssef
The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease...
June 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29667047/investigation-of-the-mechanism-of-therapeutic-protein-drug-interaction-between-methotrexate-and-golimumab-an-anti-tnf%C3%AE-monoclonal-antibody
#10
Weirong Wang, Jocelyn Leu, Rebecca Watson, Zhenhua Xu, Honghui Zhou
A prominent example of human therapeutic protein-drug interaction (TP-DI) is between methotrexate (MTX) and anti-TNFα mAbs. One plausible mechanism for this TP-DI is through the pharmacodynamic effect of MTX on immunogenicity. However, there is no definitive evidence to substantiate this mechanism, and other competing hypotheses, such as MTX suppressing FcγRI expression thereby affecting mAb PK, have also been proposed. In order to understand this mechanism, a cynomolgus monkey study was conducted using golimumab as a model compound...
April 17, 2018: AAPS Journal
https://www.readbyqxmd.com/read/29665045/high-body-mass-index-is-associated-with-increased-risk-of-treatment-failure-and-surgery-in-biologic-treated-patients-with-ulcerative-colitis
#11
S Kurnool, N H Nguyen, J Proudfoot, P S Dulai, B S Boland, N Vande Casteele, E Evans, E L Grunvald, A Zarrinpar, W J Sandborn, S Singh
BACKGROUND: Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity's impact on clinical outcomes in biologic-treated patients with ulcerative colitis (UC) is inconsistent. AIMS: To evaluate the impact of obesity on real world response to biological therapy in patients with UC. METHODS: In a single-centre retrospective cohort study between 2011-2016 of biologic-treated patients with UC, we evaluated treatment response by baseline body mass index (BMI)...
April 17, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29618976/the-efficacy-and-safety-of-mainstream-medications-for-patients-with-cdmard-na%C3%A3-ve-rheumatoid-arthritis-a-network-meta-analysis
#12
Weiyan Cai, Youyi Gu, Huanqin Cui, Yinyin Cao, Xiaoliang Wang, Yi Yao, Mingyu Wang
Background: The mainstream medications for rheumatoid arthritis (RA) include conventional disease-modifying antirheumatic drugs (cDMARDs), which mostly are methotrexate (MTX), and biologic agents such as adalimumab (ADA), certolizumab (CZP), etanercept (ETN), golimumab (GOL), infliximab (IFX), and tocilizumab (TCZ). This network meta-analysis was aimed at evaluating the efficacy and safety of the medications above and interventions combining cDMARDs and biologic agents for patients with RA. Methods: PubMed, EMBASE, Cochrane Library, and ClinicalTrials...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29611083/regional-differences-in-baseline-disease-activity-and-remission-rates-following-golimumab-treatment-for-ra-results-from-the-go-more-trial
#13
Patrick Durez, Karel Pavelka, Maria Alicia Lazaro, Abraham Garcia-Kutzbach, Robert J Moots, Howard Amital, Marinella Govoni, Nathan Vastesaeger
GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria...
May 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29603214/tumor-necrosis-factor-alpha-inhibitors-and-risk-of-non-hodgkin-lymphoma-in-a-cohort-of-adults-with-rheumatologic-conditions
#14
Gregory S Calip, Pritesh R Patel, Sruthi Adimadhyam, Shan Xing, Zhaoju Wu, Karen Sweiss, Glen T Schumock, Todd A Lee, Brian C-H Chiu
Based on limited evidence, the U.S. Food and Drug Administration (FDA) issued a black box warning for the use of tumor necrosis factor-alpha inhibitors (TNFIs) and risk of non-Hodgkin lymphoma (NHL). Our objective was to determine the risk of NHL associated with TNFI use by duration and type of anti-TNF agent. We performed a nested case-control study within a retrospective cohort of adults with rheumatologic conditions from a U.S. commercial health insurance database between 2009 and 2015. Use of TNFIs (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol) and conventional-synthetic disease-modifying antirheumatic drugs (csDMARDs) was identified, and conditional logistic regression models were used to estimate adjusted odds ratios (OR) and 95% confidence intervals (CI) for risk of NHL...
March 30, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29601563/-advances-in-differential-diagnosis-and-treatment-of-patients-with-sarcoidosis
#15
REVIEW
Tadeusz Płusa
The implementation of treatment in patients with sarcoidosis (SA) must be associated with the certainty of diagnosis, which is difficult due to the lack of unambiguous criteria. Finding the presence of noncaseating granulomas in bioptic material is not always indicative of SA. The main point of SA's diagnosis is the level of its activity, because only patients in the active stage should be qualified for treatment. In therapy, glucocorticosteroids or second-line drugs - methotrexate or azathioprine are still recommended...
March 27, 2018: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29600931/effects-of-biologic-disease-modifying-anti-rheumatic-drugs-on-the-radiographic-progression-of-rheumatoid-arthritis-a-systematic-literature-review
#16
REVIEW
Bernard Combe, Sadiq Lula, Caroline Boone, Patrick Durez
OBJECTIVES: To evaluate the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs) on radiographic progression in patients with rheumatoid arthritis (RA). METHODS: A systematic review of electronic databases and conference proceedings was conducted through January 2015, to identify randomised controlled trials (RCTs) and observational studies that assessed the impact of bDMARDs [± conventional synthetic DMARDs (csDMARDs), mainly methotrexate (MTX)], versus csDMARDs alone, on radiographic progression in patients with RA...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29582617/real-world-use-of-biological-drugs-in-patients-with-psoriasis-psoriatic-arthritis-a-retrospective-population-based-study-from-southern-italy-in-the-years-2010-2014
#17
Ilaria Marcianò, Maria P Randazzo, Paolo Panagia, Rosanna Intelisano, Carmela Sgroi, Valentina Ientile, Serafinella Cannavò, Claudio Guarneri, Paolina Reitano, Edoardo Spina, Gianluca Trifirò
BACKGROUND: Biological drugs, such as infliximab, etanercept, adalimumab, ustekinumab, golimumab and certolizumab are third-line therapy for psoriasis (PsO) and psoriatic arthritis (PsA), but they may be used at earlier stage in severe forms. This study investigated the pattern of use and costs of biological drugs for PsO/PsA in a large population from Southern Italy during the years 2010-2014. METHODS: This was a retrospective, population-based, drug-utilization study, using healthcare administrative databases of the Local Health Unit and two hospitals of Messina Province (Sicily) in the years 2010-2014...
March 26, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29575262/structural-basis-for-tumor-necrosis-factor-blockade-with-the-therapeutic-antibody-golimumab
#18
Masatsugu Ono, Shoichiro Horita, Yumi Sato, Yayoi Nomura, So Iwata, Norimichi Nomura
Tumor necrosis factor α (TNFα) is a proinflammatory cytokine, and elevated levels of TNFα in serum are associated with various autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis and systemic lupus erythaematosus. TNFα performs its pleiotropic functions by binding to two structurally distinct transmembrane receptors, TNF receptor (TNFR) 1 and TNFR2. Antibody-based therapeutic strategies that block excessive TNFα signaling have been shown to be effective in suppressing such harmful inflammatory conditions...
March 25, 2018: Protein Science: a Publication of the Protein Society
https://www.readbyqxmd.com/read/29560650/an-unusual-case-of-hamartomatous-polyposis-with-malignancy-complication-in-a-patient-with-ulcerative-colitis-treated-with-golimumab
#19
A Al Khoury, C-Y Chao, S Camilleri-Broet, T Bessissow
We report an unusual case of hamartomatous polyposis with malignant complications in a patient with ulcerative colitis on golimumab and previous thiopurine therapy. This patient was evaluated for iron deficiency anemia and underwent hemicolectomy for extensive right-side predominant inflammatory pseudopolyps. Anemia persisted post-colectomy and subsequent gastroscopy showed a fungating polypoid lesion along with numerous carpet-like strawberry appearing polyps in the stomach extending from the gastro-esophageal junction to the distal part of the antrum, necessitating a gastrectomy...
October 2017: Acta Gastro-enterologica Belgica
https://www.readbyqxmd.com/read/29558044/efficacy-and-safety-of-golimumab-as-add-on-therapy-to-standard-disease-modifying-antirheumatic-drugs-results-of-the-go-more-study-in-the-polish-population
#20
Sławomir Jeka, Bogdan Batko, Mariusz Korkosz, Maria Majdan, Brygida Kwiatkowska, Iwona Dankiewicz-Fares, Jerzy M Sobiecki, Włodzimierz Samborski
BACKGROUND: The GO-MORE study was an open-label, multinational, prospective study that investigated the efficacy and safety of adding golimumab to synthetic disease-modifying antirheumatic drugs (sDMARDs) in patients with active rheumatoid arthritis (RA). OBJECTIVES: The aim of this study was to assess the efficacy and safety of golimumab add-on therapy in the Polish subpopulation of the GO-MORE study. MATERIAL AND METHODS: Patients were administered 50 mg subcutaneous doses of golimumab once a month for 6 months, while continuing therapy with sDMARDs and/or glucocorticoids (GCS)...
March 20, 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
keyword
keyword
19896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"